A study reports that a new prostate cancer test may detect more dangerous, aggressive tumors than standard PSA (prostate-specific antigen) screening. PSA screening is widely used but can miss clinically significant cancers or identify tumors that may not become harmful. According to the article, researchers evaluated the new testing approach and found it could improve detection of higher-risk prostate cancers compared with PSA-based methods. The reporting describes the test as potentially offering better identification of tumors that pose a greater threat to patients, which could help guide treatment decisions. The sources do not provide additional details such as the study size, specific performance metrics, or how the test works, and they do not indicate whether it has been adopted in routine clinical practice. The study’s findings are presented as evidence that the new test could be more effective than current screening tools, while further validation and broader clinical evaluation would likely be needed before any change in screening protocols.